Objective: The immunosuppressive properties of azathioprine (AZA) are mediated by intracellular metabolism of 6-MP into its active metabolites 6-thiguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP). The aims of this study were to correlate red blood cell (RBC) 6-TGN and hematological parameters and their change in adult patients with Crohn's disease (CD) treated by AZA and to determine independent factors enabling determination of RBC 6-TGN.
Methods: RBC 6-TGN concentration was determined with high performance liquid chromography (HLPC) performed on 74 hepa-rinized blood samples from 32 patients. Changes of hematological parameters were measured for each RBC 6-TGN concentration. RBC 6-TGN concentration above 235 pmol/8x108 RBC was proposed as the therapeutic level in patients treated by AZA. Correlations between the various parameters were assessed as appropriate. Logistic regression analysis was used to determinate independent variables. P<0.05 was considered significant.
Results: There was a positive correlation between RBC 6-TGN and decreased red cell count (DeltaRBC) (r=0.314; P=0.006), platelet count (DeltaPlatelets) (r=0.314; P=0.007), White cell count (DeltaWC) (r=0.241; P=0.04) and neutrophil count (DeltaPMN) (r=0.292; P=0.02). RBC 6-TGN in the therapeutic zone was positively correlated with mean corpuscular volume (MCV) (r=0.527; P=0.01), mean corpuscular hemoglobin concentration (MCHC) (r=0.437; P=0.04), increase in MCV (DeltaMCV) (r=0.512; P=0.012), decrease in White cell count (DeltaWC) (r=0451; P=003) and in neutrophil count (DeltaPMN) (r=0.463; P=0.03). Multivariate analysis showed that low activity of CD (P<0.02), young age at onset of treatment by AZA (P<0.03) and a low red cell distribution width (RDW) (P=0.003) were independent factors for RBC 6-TGN situated in therapeutic zone. RBC 6-TGN could be determined by logistic regression from AZA dose (mg/kg/d) and MCV increase.
Conclusion: This study confirms that hematological parameters or their change can be used to determine whether RBC 6-TGN concentration has reached the therapeutic level. Logistic regression analysis showed that decreased RDW and increased MCV were independent factors for RBC 6-TGN level.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0399-8320(05)82219-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.
Intern Med J
November 2024
Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Article Synopsis
- Thiopurine co-therapy with anti-TNFα agents improves drug levels and reduces the chance of developing antibodies in patients with inflammatory bowel disease (IBD).* -
- A study analyzed the relationship between 6-thioguanine nucleotide (6-TGN) levels and anti-TNFα levels among IBD patients from 2015 to 2021, showing a significant link with infliximab but not adalimumab.* -
- The research identified optimal 6-TGN cut-off levels for effective therapeutic anti-TNFα levels, suggesting lower levels may suffice for treatment, particularly for infliximab.*
Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment.
Br J Clin Pharmacol
December 2024
Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands.
Aims: Conventional thiopurines (azathioprine and mercaptopurine) remain standard therapy to maintain steroid sparing remission in inflammatory bowel disease (IBD), but are regularly discontinued due to adverse drug reactions (ADRs). Measurement of the metabolites 6-thioguanine nucleotides (6-TGN), 6-methylmercaptopurine ribonucleotides (6-MMPR) and the 6-MMPR/6-TGN ratio, may predict the development of these ADRs. Our aim was to evaluate whether early thiopurine metabolite measurements were associated with clinical outcomes.
View Article and Find Full Text PDFInnovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.
Clin Pharmacokinet
August 2024
Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Article Synopsis
- - The text discusses the use of thiopurine prodrugs like thioguanine (TG), azathioprine (AZA), and mercaptopurine (MP) in treating conditions such as leukemia and inflammatory bowel disease (IBD), highlighting the importance of measuring 6-thioguanine nucleotides (6-TGNs) for monitoring treatment, although high levels can lead to side effects like leukopenia.
- - It emphasizes the potential advantage of measuring DNA-incorporated thioguanine (DNA-TG) over 6-TGNs, as DNA-TG can account for genetic variations that affect drug metabolism, particularly in various ethnic populations.
- - A systematic review and meta-analysis
Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease.
Lupus Sci Med
January 2024
Department of Medicine, Duke University, Durham, North Carolina, USA.
Article Synopsis
- This study investigates the effects of pregnancy on the metabolism of azathioprine (AZA) and its metabolites in women with rheumatic diseases, focusing on 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN).
- It includes data from 37 pregnancies and 108 blood samples, finding stable levels of 6-TGN but elevated levels of 6-MMPN during pregnancy without associated liver issues.
- The research notes a potential link between metabolite levels, maternal disease activity, and improved neonatal outcomes, although the findings on significant changes in 6-TGN levels during pregnancy were inconclusive.
Therapeutic drug monitoring of thiopurines: Effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients.
Br J Clin Pharmacol
August 2022
Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Aims: The effect of the Dutch nationwide adjustment of reducing 6-thioguanine nucleotide (6-TGN) target values (from 600-1200 to 320-630 pmol/8 × 10 red blood cells [RBC]) on toxicity and clinical outcome of thiopurine treatment in patients with inflammatory bowel disease has not yet been established. Therefore, the authors determined the incidence of toxicity-induced discontinuations and efficacy at both target concentrations.
Methods: This retrospective study was performed in inflammatory bowel disease patients treated with azathioprine or mercaptopurine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!